Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 11/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.37 |
| ▸ | PDE4A | P27815 | 8/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306377 | 0.92 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4308365 | 0.90 | BACE1 (0.37) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4308354 | 0.89 | BACE1 (0.39) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4305817 | 0.89 | PDE4D (0.36) | PDE4DPDE4BPDE4APDE4CMEN1 | |
| SCHEMBL4315734 | 0.88 | PDE4B (0.37) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4309481 | 0.87 | PTPN2 (0.36) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4310778 | 0.87 | BACE1 (0.37) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4308458 | 0.87 | PDE4D (0.37) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4304207 | 0.85 | BACE1 (0.41) | PDE4DPDE4BPDE4APDE4CBACE1 | |
| SCHEMBL4312770 | 0.85 | LMNA (0.41) | PDE4DPDE4BPDE4APDE4CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137161-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | PDE4D 955/4885PDE4B 702/4885PDE4A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.